REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 YTD Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2024-01-01 to 2024-09-30

Swipe to see the full flow
REGENERON PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2024 through Sep 30, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $3,157,700,000.00Net income → Operating adjustments reconciliation: $337,200,000.00Stock-based compensation expense → Operating adjustments reconciliation: $678,400,000.00Increase in accounts payable, accrued expenses, and other liabilities → Operating adjustments reconciliation: $509,500,000.00Depreciation and amortization → Operating adjustments reconciliation: $356,500,000.00Increase (decrease) in deferred revenue → Operating adjustments reconciliation: $249,000,000.00Operating adjustments reconciliation → Increase in inventories: $502,000,000.00Operating adjustments reconciliation → Deferred income taxes: $477,100,000.00Operating adjustments reconciliation → Increase in accounts receivable: $436,200,000.00Operating adjustments reconciliation → Increase in prepaid expenses and other assets: $352,200,000.00Operating adjustments reconciliation → (Gains) losses on marketable and other securities, net: $331,200,000.00Operating adjustments reconciliation → Other non-cash items, net: $31,900,000.00Sales or maturities of marketable and other securities → investing reconciliation: $12,445,300,000.00Proceeds from sale of property, plant, and equipment → investing reconciliation: $20,100,000.00investing reconciliation → Purchases of marketable and other securities: $14,664,500,000.00investing reconciliation → Capital expenditures: $556,300,000.00investing reconciliation → Payments for Libtayo intangible asset: $58,300,000.00investing reconciliation → Acquisitions, net of cash acquired: $5,000,000.00Net cash used in financing activities → financing reconciliation: $1,065,000,000.00Proceeds from issuance of Common Stock → financing reconciliation: $1,374,400,000.00financing reconciliation → Repurchases of Common Stock: $1,630,300,000.00financing reconciliation → Payments in connection with Common Stock tendered for employee tax obligations: $775,700,000.00financing reconciliation → Other: $33,400,000.00Net cash used in investing activities → investing reconciliation: $2,818,700,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $2,737,800,000.00Net cash from operating activities → Cash sources and uses: $3,157,700,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $2,011,800,000.00Cash sources and uses → Net cash used in investing activities: $2,818,700,000.00Cash sources and uses → Net cash used in financing activities: $1,065,000,000.00Net income: $3,494,900,000.00Net income+$3.49 BIncrease in accounts payable, accrued expenses, and other liabilities: $509,500,000.00Payables & accrued liabilities+$509.50 MIncrease in prepaid expenses and other assets: -$352,200,000.00Prepaid & other assets−$352.20 MOther non-cash items, net: -$31,900,000.00Other non-cash items−$31.90 MStock-based compensation expense: $678,400,000.00Stock-based compensation+$678.40 M(Gains) losses on marketable and other securities, net: -$331,200,000.00Marketable & other gains, net−$331.20 MIncrease in accounts receivable: -$436,200,000.00Accounts receivable−$436.20 MIncrease in inventories: -$502,000,000.00Inventories−$502.00 MDepreciation and amortization: $356,500,000.00Depreciation & amortization+$356.50 MDeferred income taxes: -$477,100,000.00Deferred tax balances−$477.10 MIncrease (decrease) in deferred revenue: $249,000,000.00Deferred revenue+$249.00 MNet cash from operating activities: $3,157,700,000.00Operating cash+$3.16 BOperating adjustments reconciliation: $2,130,600,000.00Proceeds from issuance of Common Stock: $1,374,400,000.00Common stock issued+$1.37 BPayments in connection with Common Stock tendered for employee tax obligations: -$775,700,000.00Stock-award tax withholding−$775.70 MOther: -$33,400,000.00Other financing, net−$33.40 MRepurchases of Common Stock: -$1,630,300,000.00Common stock repurchases−$1.63 BNet cash used in financing activities: -$1,065,000,000.00. Cash required to fund net payments.Financing cash−$1.07 Bfinancing reconciliation: $2,439,400,000.00Purchases of marketable and other securities: -$14,664,500,000.00Marketable securities purchases−$14.66 BAcquisitions, net of cash acquired: -$5,000,000.00Acquisitions, net of cash−$5.00 MPayments for Libtayo intangible asset: -$58,300,000.00Payments for Libtayo intangible asset−$58.30 MCapital expenditures: -$556,300,000.00Capital expenditures−$556.30 MSales or maturities of marketable and other securities: $12,445,300,000.00Marketable securities proceeds+$12.45 BProceeds from sale of property, plant, and equipment: $20,100,000.00PP&E sales+$20.10 MNet cash used in investing activities: -$2,818,700,000.00. Cash required to fund net payments.Investing cash−$2.82 Binvesting reconciliation: $15,284,100,000.00Cash sources and uses: $5,895,500,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $2,737,800,000.00Beginning cash$2.74 BEnding cash: Cash, cash equivalents, and restricted cash: $2,011,800,000.00Ending cash$2.01 BCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$2.60 BOperating cash − cash spent on productive assetsCash flow / Net income0.90×Operating cash flow ÷ net incomeNet cash change−$726.00 MEnding cash − beginning cash
Chart details

REGENERON PHARMACEUTICALS, INC. cash flow reconciliation, Jan 1, 2024 through Sep 30, 2024

Cash flows for Jan 1, 2024 through Sep 30, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2023. Ending cash: Sep 30, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2023
2,737,800,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
3,157,700,000 US dollars. Net cash provided.
Net income
3,494,900,000 US dollars
Increase in accounts payable, accrued expenses, and other liabilities
509,500,000 US dollars
Increase in prepaid expenses and other assets
negative 352,200,000 US dollars
Other non-cash items, net
negative 31,900,000 US dollars
Stock-based compensation expense
678,400,000 US dollars
(Gains) losses on marketable and other securities, net
negative 331,200,000 US dollars
Increase in accounts receivable
negative 436,200,000 US dollars
Increase in inventories
negative 502,000,000 US dollars
Depreciation and amortization
356,500,000 US dollars
Deferred income taxes
negative 477,100,000 US dollars
Increase (decrease) in deferred revenue
249,000,000 US dollars
Investing activities
negative 2,818,700,000 US dollars. Net cash used.
Purchases of marketable and other securities
negative 14,664,500,000 US dollars
Acquisitions, net of cash acquired
negative 5,000,000 US dollars
Payments for Libtayo intangible asset
negative 58,300,000 US dollars
Capital expenditures
negative 556,300,000 US dollars
Sales or maturities of marketable and other securities
12,445,300,000 US dollars
Proceeds from sale of property, plant, and equipment
20,100,000 US dollars
Financing activities
negative 1,065,000,000 US dollars. Net cash used.
Proceeds from issuance of Common Stock
1,374,400,000 US dollars
Payments in connection with Common Stock tendered for employee tax obligations
negative 775,700,000 US dollars
Other
negative 33,400,000 US dollars
Repurchases of Common Stock
negative 1,630,300,000 US dollars
Operating adjustment reconciliation
2,130,600,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
2,439,400,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
15,284,100,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2024
2,011,800,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
5,895,500,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 726,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.90×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
3,157,700,000 US dollars. Operating cash flow used in the free cash flow calculation.
cash spent on productive assets
556,300,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
2,601,400,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $3.16B of net income directly to operating cash and $337.20M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash spent on productive assets equals free cash flow: 3,157,700,000 US dollars minus 556,300,000 US dollars equals 2,601,400,000 US dollars.
REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!